Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-12-01 pm EST
61.25 USD   -1.34%
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Coronary Artery Disease Detection

09/13/2022 | 09:21am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GENERAL ELECTRIC COMPANY -0.83% 85.26 Delayed Quote.-9.00%
LANTHEUS HOLDINGS, INC. -1.34% 61.25 Delayed Quote.112.01%
All news about LANTHEUS HOLDINGS, INC.
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
GL
11/29Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial
CI
11/28Lantheus Holdings Secures Chinese Approval for Ultrasound Enhancing Agent
MT
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China's ..
GL
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China's ..
AQ
11/28Lantheus Announces the Approval of DEFINITY« (Perflutren Lipid Microsphere) by China..
CI
11/14POINT Biopharma Global Posts Wider Q3 Loss, Signs License Agreements With Lantheus; Sha..
MT
11/14Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Other Events, Financ..
AQ
11/14Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agr..
GL
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 22,0x
Yield 2022 -
Capitalization 4 273 M 4 273 M -
Capi. / Sales 2022 4,66x
Capi. / Sales 2023 4,13x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 62,08 $
Average target price 101,67 $
Spread / Average Target 63,8%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors